ArticleBlood2015

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.

Achim Rothe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.